Home › STANBIO LABORATORY, L.P. › Total & Direct Bilirubin LiquiColor®
Total & Direct Bilirubin LiquiColor®
STANBIO LABORATORY, L.P. · Model 0260-200 · UDI-DI 00657498000601
CIG
Prescription
10
510(k) clearances
399
Adverse events
19
Recalls
48
Facilities
Description
For the Quantitative Colorimetric Determination of Total and Direct Bilirubin in Serum or Plasma.
Recalls
| Date | Firm | Reason |
|---|---|---|
| 2024-07-30 | Siemens Healthcare Diagnostics, Inc. | During manufacturing, the last three tests from the 160 test flex of lot 23206BA (wells 8 or 10) were processed on the Dimension Vista platform. There was an issue with the filling |
| 2023-08-05 | Ortho-Clinical Diagnostics, INc. | Samples containing high levels of ALKP (or an interfering substance) could deplete the available substrate in the reagent layer of a VITROS ALKP Slide and not post the substrate de |
| 2020-07-13 | Ortho-Clinical Diagnostics | Etrombopag Interference for VITROS Chemistry Products: TBIL Slides, VITROS BuBc Slides and VITROS XT TBIL-ALKP Slides |
| 2020-07-13 | Ortho-Clinical Diagnostics | Etrombopag Interference for VITROS Chemistry Products: TBIL Slides, VITROS BuBc Slides and VITROS XT TBIL-ALKP Slides |
| 2020-02-13 | Siemens Healthcare Diagnostics, Inc. | Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy |
| 2020-02-13 | Siemens Healthcare Diagnostics, Inc. | Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy |
| 2019-09-11 | Roche Diagnostics Operations, Inc. | Due to low Quality Control recovery and invalid Calibration. |
| 2019-08-15 | Beckman Coulter Inc | It has been determined that N-acetyl p benzoquinone imine (NAPQI), a metabolite of acetaminophen (paracetamol), may cause negative interference for assays if present in high quanti |
| 2019-08-15 | Beckman Coulter Inc | It has been determined that N-acetyl p benzoquinone imine (NAPQI), a metabolite of acetaminophen (paracetamol), may cause negative interference for assays if present in high quanti |
| 2018-12-17 | Roche Diagnostics Corporation | New endogenous interference claims have been established for the following assays used on the cobas c 311 analyzer and the cobas c 501, 502, 701, 702, and Modular Analytics P/D mod |
Query this across every FDA database — by API.
Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.
Get your free API keyRead the docsData compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.